Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hamm – page 3

40 clinical trials in Hamm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hamm at a glance
40
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

40 trials in Hamm

Open in trial search

Gastrooesophageal cancer

Not recruiting

Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Dermatitis atopic

Not recruiting

Study Comparing Methylprednisolone Aceponate Ointment and a Drug Combination for Patients with Mild to Moderate Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Methylprednisolone Aceponate
  • Sponsor:Dermapharm AG

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Acute myeloid leukaemia

Not recruiting

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Non-small cell lung cancer

Not recruiting

Study on Afatinib and Osimertinib for Patients with EGFR-Mutated, T790M Negative Non-Squamous Non-Small Cell Lung Cancer in First-Line Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Plasma cell myeloma

Not recruiting

Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Non-small cell lung cancer stage III

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Hamm

What the registry says about research in the country

01 Hematologic Oncology

Innovative clinical trials focusing on blood cancers and related disorders, including studies of new treatment approaches for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.

  • Novel drug combinations for CLL/SLL treatment
  • Multiple myeloma therapies
  • Advanced leukemia treatments

Research emphasizes personalized medicine approaches and targeted therapies to improve patient outcomes.

02 Solid Tumors

Comprehensive research into various types of solid tumors, with particular focus on breast cancer, lung cancer, and gastrointestinal cancers.

  • Triple-negative breast cancer treatments
  • Non-small cell lung cancer therapies
  • Colon cancer interventions

Studies explore both neoadjuvant and adjuvant treatment approaches.

03 Dermatological Conditions

Clinical investigations of various skin conditions, including actinic keratosis, rosacea, and atopic dermatitis.

  • Novel topical treatments
  • Comparative efficacy studies
  • Inflammatory skin conditions

Research focuses on both innovative and established therapeutic approaches for skin disorders.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.